Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too

Sep 24 2017

• By Michael Cipriano

Keeping Track Feature image

Related Content

Keeping Track: A Good Week For Biologics And Probuphine, Less So For Eteplirsen And ZS-9

May 30 2016

Keeping Track: Allergan Antipsychotic <em>Vraylar</em> Approved; First-Line <em>Imbruvica</em> Claim Submitted

Sep 21 2015

Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER

Jun 09 2017

Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot

Jul 25 2017

US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab

Aug 08 2017

Janssen's Sirukumab Falls On Mortality Concerns At US FDA Panel

Aug 03 2017

Antibiotic Pipeline Profile: Balancing Broad Spectrum And Limited Use

Jul 05 2017

Related Companies

Paratek Pharmaceuticals, Inc.

LigaChem Biosciences

Apple Tree Partners

Camurus AB

Allergan plc

Johnson & Johnson

Johnson & Johnson

Merck & Co., Inc.

Johnson & Johnson

AbbVie Inc.

Titan Pharmaceuticals Inc.

Additional Topics

United States Drug Review Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window